Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Structural and sequence variants in patients with Silver-Russell syndrome or similar features-Curation of a disease database

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Nonaspirin NSAIDs and contralateral breast cancer risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Low-dose aspirin use and risk of contralateral breast cancer: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Susan J Ramus
  • Antonis C Antoniou
  • Karoline B Kuchenbaecker
  • Penny Soucy
  • Jonathan Beesley
  • Xiaoqing Chen
  • Lesley McGuffog
  • Olga M Sinilnikova
  • Sue Healey
  • Daniel Barrowdale
  • Andrew Roger Lee
  • Mads Thomassen
  • Anne-Marie Gerdes
  • Torben A Kruse
  • Uffe Birk Jensen
  • Anne-Bine Skytte
  • Maria A Caligo
  • Annelie Liljegren
  • Annika Lindblom
  • Håkan Olsson
  • Ulf Kristoffersson
  • Marie Stenmark-Askmalm
  • Beatrice Melin
  • Susan M Domchek
  • Katherine L Nathanson
  • Timothy R Rebbeck
  • Anna Jakubowska
  • Jan Lubinski
  • Katarzyna Jaworska
  • Katarzyna Durda
  • Elżbieta Złowocka
  • Jacek Gronwald
  • Tomasz Huzarski
  • Tomasz Byrski
  • Cezary Cybulski
  • Aleksandra Toloczko-Grabarek
  • Ana Osorio
  • Javier Benitez
  • Mercedes Duran
  • Maria-Isabel Tejada
  • Ute Hamann
  • Matti Rookus
  • Flora E van Leeuwen
  • Cora M Aalfs
  • Hanne E J Meijers-Heijboer
  • Christi J van Asperen
  • K E P van Roozendaal
  • Nicoline Hoogerbrugge
  • Thomas v O Hansen
  • Bent Ejlertsen
  • SWE-BRCA
View graph of relations
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.67-0.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.21-1.83) P-trend = 1.8 × 10(-4), rs717852 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.6 × 10(-4), rs9303542 HR = 1.16 (95% CI: 1.02-1.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.81-0.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.10-1.42) P-trend = 6.1 × 10(-4). The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer.
Original languageEnglish
JournalHuman Mutation
Volume33
Issue number4
Pages (from-to)690-702
Number of pages13
ISSN1059-7794
DOIs
Publication statusPublished - 2012

    Research areas

  • Adult, BRCA1 Protein, BRCA2 Protein, Cohort Studies, Female, Genetic Predisposition to Disease, Heterozygote, Humans, Middle Aged, Mutation, Odds Ratio, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Retrospective Studies

ID: 36600329